Northwest Biotherapeutics (OTCMKTS:NWBO) Share Price Crosses Below Two Hundred Day Moving Average – Here’s Why

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO)’s stock price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.25 and traded as low as $0.24. Northwest Biotherapeutics shares last traded at $0.2410, with a volume of 1,274,155 shares.

Northwest Biotherapeutics Stock Performance

The company has a fifty day simple moving average of $0.24 and a two-hundred day simple moving average of $0.25. The firm has a market capitalization of $379.09 million, a PE ratio of -0.01 and a beta of -0.84.

Northwest Biotherapeutics (OTCMKTS:NWBO) last released its quarterly earnings data on Friday, November 14th. The biotechnology company reported ($18.22) earnings per share for the quarter. The company had revenue of $0.20 million during the quarter.

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company’s proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient’s tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies.

The company’s lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial.